share_log

Takeda Receives Positive CHMP Opinion For Maribavir For The Treatment Of Adults With Post-transplant Cytomegalovirus (CMV) Refractory (With Or Without Resistance) To Prior Therapies

Benzinga Real-time News ·  Sep 16, 2022 08:06
Takeda Receives Positive CHMP Opinion For Maribavir For The Treatment Of Adults With Post-transplant Cytomegalovirus (CMV) Refractory (With Or Without Resistance) To Prior Therapies
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment